Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.47 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.47 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.45 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.45 |
| ▸ | BRD4 | O60885 | 14/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15894555 | 0.94 | SUV39H2 (0.51) | STK17BSTK17APCSK9SUV39H2BRD4 | |
| SCHEMBL15891391 | 0.84 | CA12 (0.45) | STK17BSTK17APCSK9SUV39H2BRD4 | |
| SCHEMBL15891328 | 0.84 | RET (0.41) | PCSK9SUV39H2PIM1PIM2 | |
| SCHEMBL30103007 | 0.81 | PIM1 (0.40) | PIM1PIM2 | |
| SCHEMBL18386990 | 0.81 | ADORA3 (0.49) | PCSK9SUV39H2BRD4PIM1PIM2 | |
| SCHEMBL14830820 | 0.80 | CSNK2A1 (0.47) | STK17BSTK17APCSK9BRD4PIM1 | |
| SCHEMBL15280689 | 0.80 | RET (0.48) | PCSK9SUV39H2PIM1PIM2 | |
| SCHEMBL16083665 | 0.80 | PCSK9 (0.49) | PCSK9SUV39H2 | |
| SCHEMBL15894530 | 0.80 | RET (0.35) | PCSK9SUV39H2PIM1PIM2JAK2 | |
| SCHEMBL15261632 | 0.78 | PIM1 (0.45) | PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970333-B1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | IPSEN PHARMA SAS (FR) | 2017-05-03 | — | — | EP | disclosed |
| US-9370519-B2 | Macrocyclic FLT3 kinase inhibitors | ONCODESIGN S.A. (FR) | 2016-06-21 | — | — | US | disclosed |
| US-9370519-B2 | Macrocyclic FLT3 kinase inhibitors | ONCODESIGN S.A. (FR) | 2016-06-21 | — | — | US | disclosed |
| US-20160031905-A1 | Macrocyclic LRRK2 Kinase Inhibitors | ONCODESIGN S.A. (FR) | 2016-02-04 | — | — | US | disclosed |
| US-20160031905-A1 | Macrocyclic LRRK2 Kinase Inhibitors | ONCODESIGN S.A. (FR) | 2016-02-04 | — | — | US | disclosed |
| US-20150283141-A1 | MACROCYCLIC FLT3 KINASE INHIBITORS | ONCODESIGN SA (FR) | 2015-10-08 | — | — | US | disclosed |
| US-20150283141-A1 | MACROCYCLIC FLT3 KINASE INHIBITORS | ONCODESIGN SA (FR) | 2015-10-08 | — | — | US | disclosed |
| US-9090630-B2 | Macrocyclic FLT3 kinase inhibitors | ONCODESIGN S.A. (FR) | 2015-07-28 | — | — | US | disclosed |
| US-9090630-B2 | Macrocyclic FLT3 kinase inhibitors | ONCODESIGN S.A. (FR) | 2015-07-28 | — | — | US | disclosed |
| US-20140303159-A1 | MACROCYCLIC FLT3 KINASE INHIBITORS | ONCODESIGN S.A. (FR) | 2014-10-09 | — | — | US | disclosed |
| US-20140303159-A1 | MACROCYCLIC FLT3 KINASE INHIBITORS | ONCODESIGN S.A. (FR) | 2014-10-09 | — | — | US | disclosed |
| WO-2014140235-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | IPSEN PHARMA S.A.S. (FR) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303159-A1 | MACROCYCLIC FLT3 KINASE INHIBITORS | FLT3, ABL1, FER | STK17B 100/4885STK17A 107/4885PCSK9 1957/4885 |
| US-20150283141-A1 | MACROCYCLIC FLT3 KINASE INHIBITORS | FLT3, ABL1, FER | STK17B 100/4885STK17A 107/4885PCSK9 1957/4885 |
| US-20160031905-A1 | Macrocyclic LRRK2 Kinase Inhibitors | LRRK2, PINK1, PARK7 | STK17B 96/4885STK17A 118/4885PCSK9 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.